Hennion & Walsh Asset Management, Inc. Vertex Pharmaceuticals Inc Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.06 Billion
- Q3 2024
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 7,572 shares of VRTX stock, worth $3.54 Million. This represents 0.17% of its overall portfolio holdings.
Number of Shares
7,572
Previous 7,589
0.22%
Holding current value
$3.54 Million
Previous $3.56 Million
1.01%
% of portfolio
0.17%
Previous 0.19%
Shares
9 transactions
Others Institutions Holding VRTX
# of Institutions
1,724Shares Held
222MCall Options Held
1.58MPut Options Held
1.36M-
Capital World Investors Los Angeles, CA26.8MShares$12.6 Billion1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.2MShares$10.8 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.98 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$5.53 Billion0.23% of portfolio
-
Capital Research Global Investors Los Angeles, CA9MShares$4.21 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $120B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...